Ind-Swift Labs. Q1 FY27 Earnings Call — Analysis (NSE: INDSWFTLAB)
Ind-Swift Laboratories delivers a margin-transformation quarter as own-brand export mix hits 57% and CDMO partnerships with Viatris, Manx, and Arrotex are commercialised, setting up FY27 revenue of ~₹900 Cr.
Result quality: stable — Steady quarter. Management sentiment: optimistic.
The take
Q1FY27 Operating Income ₹186.08 Cr ( +21.16% YoY ) . New guidance — FY27 cdmo partnerships revenue (viat… ₹200 to ₹220 Cr . New story: CDMO commercialization with global partners .
Results
Operating income ₹186.08 Cr +21.16% YoY; Operating EBITDA ₹33.32 Cr +2.85x YoY; EBITDA margin 17.91% (+1,258 bps); PAT ₹24.68 Cr +2.04x YoY.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Operating Income | ₹186.08 Cr | +21.16% | yoy · Q1FY27 · over Q1FY26 |
| Operating EBITDA | ₹33.32 Cr | +2.85x | yoy · Q1FY27 · over Q1FY26 |
| Operating EBITDA Margin | 17.91% | +1258 bps | yoy · Q1FY27 · over Q1FY26 |
| PAT (excl. exceptional) | ₹24.68 Cr | +2.04x | yoy · Q1FY27 · over Q1FY26 |
| Export Own-Brands Share of Sales | 57.20% | +920 bps | yoy · Q1FY27 · over Q1FY26 |
Guidance
FY27 export sales targeted at ~₹750 Cr (CDMO 45%), overall revenue ~₹900 Cr with EBITDA margins sustainably above 18%; FY30 aspirational revenue of ₹1,500 Cr and net profit ₹200+ Cr.
What management committed to
- Incremental revenue from CDMO partnerships with Viatris, Manx (UK), and Arrotex (Australia) will be ₹200-₹220 crore in FY27. — ₹200 to ₹220 crore, FY27
- Revenue from the Viatris CDMO partnership (Ibuprofen and Clarithromycin granules) will be ₹100-₹130 crore in FY27 and reach approximately ₹200 crore cumulatively over two years (FY27-FY28). — ₹100-130 crore (FY27); ₹200 crore cumulative over two years, FY27
- Total export sales in FY27 will be ₹750 crore, with CDMO business comprising approximately 45%. — ₹750 crore; 45%, FY27
- Overall FY27 revenue is expected to be approximately ₹900 crore, implying about 50% growth YoY, subject to timely completion of capacity expansion. — ₹900 crore, FY27
- Standard operating EBITDA margin is sustainable at 18% and can rise to 21-22% as sales increase quarter-on-quarter. — 18% (sustainable), 21-22% upside, sustainably
- Total capex of ₹250 crore will be deployed over the next 2.5 years for the Jammu facility, a new warehouse, and capacity enhancement of existing production lines. — ₹250 crore, FY29
- Total dossiers filed will increase to 2,500 by Q4 FY27 (from 2,100 as of Q1 FY27). — 2,500, Q4FY27
- Revenue in FY30 will be at least ₹1,500 crore and net profit approximately ₹200+ crore. — ₹1,500 crore revenue; ₹200+ crore net profit, FY30
- No divestment of the 7.8% stake in Synthimed is planned in FY27. — FY27
- If deals are signed with two prospective new CDMO customers, required incremental capex will be ₹50-75 crore and incremental revenue will exceed ₹150 crore. — ₹50-75 crore capex; ₹150+ crore revenue
Key themes
Export-led margin expansion and CDMO commercialisation
How the narrative shifted
- CDMO commercialization with global partners: Management highlights three new CDMO partnerships commercialised, expected to add ₹200-220 Cr in FY27, anchoring the growth story.
- Own-brand export mix surge driving margins: Own-brand exports jumped to 57% of sales, driving EBITDA margin to 17.9%, with expectations of further improvement to 21-22%.
- Capacity expansion to support long-term growth: Management outlines ₹250 Cr capex over 2-2.5 years for Jammu, warehouse, and production lines to meet CDMO and own-brand demand.
- Leveraging API heritage for formulation pipeline: R&D pipeline draws from legacy API molecules (Rosuvastatin, Mirabegron, Sitagliptin, Empagliflozin) with customer-funded development, ensuring capital discipline.
- Conservative formal targets with upside potential: Management signals FY29 ₹1,200 Cr target may be beaten but avoids premature revision, while hinting at FY30 ₹1,500 Cr aspiration.
- No immediate monetization of Synthimed stake: CFO indicates holding Synthimed for longer term, citing tag-along right with PE exit, and no divestment plans this year.
Operational commentary
- CDMO partnerships with Viatris (Ibuprofen, Clarithromycin granules), Manx (UK), and Arrotex (Australia) were commercialised; expected to contribute incremental revenue of ₹200-220 Cr in FY27.
- Export own-brand share jumped to 57.2% of quarterly sales (vs 48% in Q1FY26), driving margin expansion as the mix tilts away from lower-margin contract manufacturing.
- Two new products launched: Ibuprofen Sachet for the European market and Macrogol Sachet for the UK and Australian markets.
- Total dossiers filed crossed 2,100 (up from 1,915+), and global product registrations exceeded 850 (up from 750+), expanding regulatory market reach.
- Upgrade of the Samba manufacturing facility to EU-GMP and PIC/S standards is underway to support filings across regulated markets and future export growth.
- Product-wise revenue performance: Atorvastatin FY26 revenue ₹85.50 Cr (from ₹47.96 Cr); Ezetimibe+Atorvastatin grew 247% to ₹80.78 Cr; Fexofenadine steady at ~₹74 Cr; Quetiapine nearly doubled to ₹19.75 Cr; Famciclovir more than doubled to ₹18.64 Cr.
- Upcoming launches: Clarithromycin dry suspension expected in FY27; Esomeprazole with Viatris and Arrotex expected in FY28.
Analyst Q&A
Q. What was the CDMO partnership contribution this quarter, and what growth trajectory is expected over the next three years?
The two Viatris products (Ibuprofen and Clarithromycin) booked only ₹5-6 Cr in Q1; they are expected to contribute ₹100-130 Cr in FY27 and the full ₹200 Cr will be realized over two years, not all in year one.
Q. Is the 18% EBITDA margin sustainable, and what is the margin upside?
18% is fully sustainable; with quarter-on-quarter sales increase, margins could reach 21-22%.
Q. Given current growth, isn't the FY29 ₹1,200 Cr revenue target too conservative; any revision likely?
Not at this stage; the company may revise after overachieving this financial year, but does not want to overproject.
Q. What is the addressable market size for CDMO/FDF products and details on the differentiated packaging?
These are technical questions; the CFO said he will get back through the IR partners.
Q. Can you name the two new customers being discussed for CDMO partnerships?
Names cannot be shared at this stage; waiting for the agreement to be signed, after which details will be disclosed.
Research and educational content only. Not investment advice.